Results of initial treatment, outcome, and late toxicities by treatment group
. | Not randomized for consolidation . | . | . | MOPP/ABV×8 . | . | . | ABVPP×8 . | . | . | MOPP/ABV×6 + RTx . | . | . | ABVPP×6 + RT . | . | . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | ||||||||||
Initial treatment | 39 | 29 | 47 | 84 | 3 | 5 | 114 | 0 | 2 | 108 | 1 | 5 | 86 | 2 | 8 | ||||||||||
Follow-up | |||||||||||||||||||||||||
Alive first CR | 27 | 19 | 1 | 64 | 0 | 0 | 81 | 0 | 1 | 91 | 1 | 0 | 66 | 1 | 0 | ||||||||||
Alive second CR | 4 | 4 | 2 | 6 | 1 | 0 | 21 | 0 | 1 | 4 | 0 | 0 | 6 | 0 | 0 | ||||||||||
Alive with disease | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
Died | 8 | 5 | 43 | 14 | 2 | 5 | 11 | 0 | 0 | 13 | 0 | 5 | 14 | 1 | 8 | ||||||||||
Late toxicities | |||||||||||||||||||||||||
Cancer | 8 | 2 | 0 | 7 | 0 | 0 | 5 | 0 | 0 | 8 | 0 | 0 | 6 | 0 | 0 | ||||||||||
Nonmalignant | 7 | 8 | 8 | 14 | 3 | 0 | 18 | 0 | 1 | 24 | 0 | 0 | 15 | 0 | 2 |
. | Not randomized for consolidation . | . | . | MOPP/ABV×8 . | . | . | ABVPP×8 . | . | . | MOPP/ABV×6 + RTx . | . | . | ABVPP×6 + RT . | . | . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | Primary CR . | CR after salvage . | Failure . | ||||||||||
Initial treatment | 39 | 29 | 47 | 84 | 3 | 5 | 114 | 0 | 2 | 108 | 1 | 5 | 86 | 2 | 8 | ||||||||||
Follow-up | |||||||||||||||||||||||||
Alive first CR | 27 | 19 | 1 | 64 | 0 | 0 | 81 | 0 | 1 | 91 | 1 | 0 | 66 | 1 | 0 | ||||||||||
Alive second CR | 4 | 4 | 2 | 6 | 1 | 0 | 21 | 0 | 1 | 4 | 0 | 0 | 6 | 0 | 0 | ||||||||||
Alive with disease | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
Died | 8 | 5 | 43 | 14 | 2 | 5 | 11 | 0 | 0 | 13 | 0 | 5 | 14 | 1 | 8 | ||||||||||
Late toxicities | |||||||||||||||||||||||||
Cancer | 8 | 2 | 0 | 7 | 0 | 0 | 5 | 0 | 0 | 8 | 0 | 0 | 6 | 0 | 0 | ||||||||||
Nonmalignant | 7 | 8 | 8 | 14 | 3 | 0 | 18 | 0 | 1 | 24 | 0 | 0 | 15 | 0 | 2 |
There were 115 patients not randomized for consolidation; 92 who received MOPP/ABV×8; 116 who received ABVPP×8; 114 who received MOPP/ABV×6 plus RTx; and 96 who received ABVPP×6 plus RT.